Pancreatic Cancer Research

ResearcherMedical University of LodzActive in the last 2 years

Ewa I. Malecka-Panas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1825-1807; OpenAlex author ID A5084861756. Sources: OpenAlex.

Their work

Papers
39 (first author 3, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 6 papers · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 8 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 39

  1. Liquid Biopsy-Derived microRNAs in Pancreatic Ductal Adenocarcinoma: Matrix-Specific Evidence and Translational Challenges. Last author DOI 10.3390/ijms27125468↗
  2. Can AI Be Useful in the Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes? Last author DOI 10.3390/biomedicines13040836↗
  3. Changes Connected to Early Chronic Pancreatitis and Early Pancreatic Cancer in Endoscopic Ultrasonography (EUS): Clinical Implications. Last author DOI 10.3390/cancers17111891↗
  4. Tumor Characteristics and Clinical Features of the Patient as Prognostic Factors in PDAC. Last author DOI 10.3390/cancers17203350↗
  5. Select Endocrine Disorders and Exosomes in Early PDAC Diagnosis. Last author DOI 10.3390/ijms252212159↗
  6. Gaps and Opportunities in the Diagnosis and Treatment of Pancreatic Cancer. First author DOI 10.3390/cancers15235577↗
  7. CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation. Last author DOI 10.3390/jcm12124050↗
  8. Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors. First author DOI 10.3390/jcm12134318↗
  9. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  10. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool? Co-author DOI 10.1080/15384047.2021.1941584↗
  11. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  12. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  13. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  14. Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers-Is There Anything in Sight? First author DOI 10.3390/jcm10225463↗
  15. Alpha Smooth Muscle Actin (αSMA) Immunohistochemistry Use in the Differentiation of Pancreatic Cancer from Chronic Pancreatitis. Last author DOI 10.3390/jcm10245804↗
  16. Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pa… Co-author DOI 10.5114/pg.2020.95091↗
  17. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  18. Serum Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 2 as a Novel Biomarker in the Detection of Pancreatic Adenocarcinom… Co-author DOI 10.1097/mcg.0000000000001297↗
  19. Clinical significance of activin A and myostatin in patients with pancreatic adenocarcinoma and progressive weight loss. Last author DOI 10.26402/jpp.2020.1.10↗
  20. Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma. Last author DOI 10.3390/medicina56120677↗
  21. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  22. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Last author DOI 10.5114/pg.2019.83422↗
  23. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  24. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  25. The Role of Insulin-like Growth Factor (IGF) Axis in Early Diagnosis of Pancreatic Adenocarcinoma (PDAC). Last author DOI 10.1097/mcg.0000000000001073↗
  26. Evaluation of insulin-like growth factor (IGF-1) and retinol binding protein (RBP-4) levels in patients with newly diagnosed pancreatic adenocarcinoma (PDAC). Last author DOI 10.1016/j.pan.2017.04.001↗
  27. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  28. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Last author DOI 10.1155/2017/3276806↗
  29. Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer. Last author DOI 10.1007/s10620-015-3972-6↗
  30. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  31. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  32. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  33. Analysis of XRCC2 and XRCC3 gene polymorphisms in pancreatic cancer. Last author DOI 10.3892/br.2015.550↗
  34. Utility of different serum fibrosis markers in diagnosing patients with chronic pancreatitis and pancreatic adenocarcinoma. Co-author DOI 10.4251/wjgo.v8.i8.635↗
  35. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  36. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  37. Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis. Last author DOI 10.1016/j.advms.2014.08.003↗
  38. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  39. Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer. Last author DOI 10.1016/j.pan.2013.04.198↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renata Talar‐Wojnarowska · 14 shared papers, 2013–2024 · strength 1.32
  2. Barbara Włodarczyk · 6 shared papers, 2017–2024 · strength 1.07
  3. Łukasz Durko · 4 shared papers, 2017–2025 · strength 1.02
  4. Anita Gąsiorowska · 10 shared papers, 2013–2021 · strength 0.92
  5. Natalia Pawelec · 1 shared paper, 2025 · strength 0.42
  6. Marek Olakowski · 4 shared papers, 2014–2020 · strength 0.39
  7. Natalia Michalak · 1 shared paper, 2023 · strength 0.39
  8. Miłosz Caban · 1 shared paper, 2023 · strength 0.39
  9. Maria Wołyniak · 1 shared paper, 2026 · strength 0.39
  10. Maja Mejza · 1 shared paper, 2025 · strength 0.37
  11. Karina Udrycka · 1 shared paper, 2025 · strength 0.37
  12. Janusz Strzelczyk · 3 shared papers, 2017–2021 · strength 0.31
  13. Monika Kapszewicz · 1 shared paper, 2021 · strength 0.28
  14. Katarzyna Winter · 2 shared papers, 2019–2021 · strength 0.23
  15. Tomasz Mackiewicz · 1 shared paper, 2021 · strength 0.19
  16. Aleksandra Tarasiuk · 1 shared paper, 2021 · strength 0.19
  17. Jakub Fichna · 1 shared paper, 2021 · strength 0.19
  18. Paweł Lampe · 3 shared papers, 2014–2019 · strength 0.19
  19. Leszek Czupryniak · 3 shared papers, 2013–2016 · strength 0.18
  20. Maria Gazouli · 4 shared papers, 2013–2018 · strength 0.16
  21. Federico Canzian · 4 shared papers, 2013–2018 · strength 0.16
  22. Niccola Funel · 4 shared papers, 2013–2018 · strength 0.16
  23. Gabriele Capurso · 4 shared papers, 2013–2018 · strength 0.16
  24. Daniele Campa · 4 shared papers, 2013–2018 · strength 0.16
  25. Francesca Tavano · 4 shared papers, 2013–2018 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.